Second primary tumours in laryngeal cancer

Area of Science:

• Oncology
• Cancer Research
• Epidemiology

Background:

• Laryngeal cancer patients have a notable risk of developing second primary tumors, particularly in the upper aerodigestive tract and lungs.
• The incidence of these secondary tumors varies, with higher rates observed in supraglottic cancer compared to glottic cancer, and in males versus females.
• Tobacco and alcohol consumption are identified as key risk factors contributing to the development of second primary tumors.

Purpose of the Study:

• To investigate the incidence and risk factors associated with second primary tumors in laryngeal cancer patients.
• To evaluate the effectiveness of early detection and chemoprevention strategies in managing the risk of secondary malignancies.
• To present preliminary data from the EUROSCAN study, a major chemoprevention trial in head and neck cancer.

Main Methods:

• Review of epidemiological data on second primary tumor development in laryngeal cancer cohorts.
• Analysis of risk factors, including tobacco and alcohol use.
• Presentation of preliminary findings from the EUROSCAN (European Randomized study of CHEMoprevention) trial.

Main Results:

• Second primary tumors occur in 3.8-20.5% of laryngeal cancer patients.
• Secondary tumors are found in the upper aerodigestive tract (2.2-15.3%) and lungs (1.1-12%).
• Higher incidence in supraglottic cancer, males, and in patients with a history of tobacco and alcohol use.

Conclusions:

• Second primary tumors represent a significant challenge in laryngeal cancer management, often associated with poor prognosis.
• Early detection and chemoprevention are vital approaches to mitigate the risk and impact of these secondary malignancies.
• The EUROSCAN study holds promise for advancing chemoprevention strategies in head and neck cancer patients.